standard-of-careData supported by higher objective response rate (ORR) (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment and immune system to overcome tumor immune evasion and drug resistance, today announced positive interim data from its randomized, controlled, open label, multicenter Phase 2 study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma (PDAC) presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Purple Biotech Ltd，一家临床阶段公司，开发利用肿瘤微环境和免疫系统的力量克服肿瘤免疫逃避和耐药性的一流疗法，今天宣布了其在二线转移中对CM24进行的随机、对照、开放标签、多中心2期研究的积极中期数据胰腺导管腺癌（PDAC）在2024年美国临床肿瘤学会（ASCO）年会上发表了一篇最新的摘要海报。

“These exciting interim data demonstrate the potential of CM24 in combination with nivolumab plus the standard-of-care chemotherapy regimen Nal-IRI/5FU/LV to improve clinical outcomes for advanced metastatic PDAC patients. We are highly encouraged by the meaningful results of our primary endpoint, Overall Survival, as well as by the concordant and consistent improvement in all secondary endpoints including PFS, ORR, DCR and CA19-9” stated Gil Efron, Chief Executive Officer of Purple Biotech.

Purple Biotech首席执行官吉尔·埃夫隆（Gil Efron）表示：“这些令人兴奋的中期数据表明，CM24联合nivolumab加上标准化疗方案Nal IRI/5FU/LV有可能改善晚期转移性PDAC患者的临床结局。我们对主要终点的有意义结果，总体生存率以及所有次要终点（包括PFS，ORR，DCR和CA19-9）的一致和一致的改善感到鼓舞。”。